Open AccessAdjuvant treatment for Stage I seminoma: Why radiotherapy is better than carboplatin
Author(s) -
Prahlad H Yathiraj,
Krishna Sharan,
Donald J Fernandes,
M S Vidyasagar
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.176171
Subject(s) - carboplatin , seminoma , radiation therapy , medicine , stage (stratigraphy) , chemotherapy , adjuvant , adjuvant radiotherapy , oncology , adjuvant chemotherapy , cisplatin , cancer , breast cancer , paleontology , biology
Adjuvant treatment options for Stage I seminoma include active surveillance, chemotherapy, and radiotherapy. Active surveillance may not be ideal for the average Indian patient. Of the two accepted adjuvant therapy options, namely single-dose carboplatin chemotherapy and radiotherapy to the retroperitoneal nodes, though it intuitively appears more appealing, a deeper review reveals the potential drawbacks of chemotherapy. This article highlights the misconceptions regarding carboplatin and provides reasons for an argument why radiotherapy is better when a patient with Stage I seminoma chooses to undergo adjuvant treatment.